Cullinan Therapeutics Announces First Patient Dosed In Pivotal Phase 2 Study Of CLN-049 In Relapsed AML; Expects Phase 1 Update In December
Share
Why It Matters
Cullinan started testing a new leukemia medicine in patients. Watch for updates in December to see if early results look promising.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.